Total
0
Shares
Azure Healthcare’s (ASX:AZV) subsidiary wins $1.6M contract
  • Azure Healthcare's (AZV) subsidiary, Austco Canada, has been awarded a $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital
  • The contract was from building and construction company EllisDon who are building the hospital
  • Austco's technology will be integrated with EllisDon's technology which will enhance communication between patients and caregivers
  • The new hospital is expected to be completed in 2023
  • On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.

Azure Healthcare's (AZV) subsidiary, Austco Canada, has received $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital.

The technology enables nurse call alarms to be monitored with alarm and response data then collected to measure the performance outcomes.

Austco Canada was picked by construction and building services company EllisDon as its software is the most flexible and advanced.

The new hospital is currently construction and is expected to be completed in 2023, with the Austco Tacera system expected to be delivered in 2022.

All beds will feature the Austco Patient System which will be integrated with EllisDon’s Building Management System. Both systems will enhance communication between patients and caregivers.

"We are committed to providing innovative solutions that deliver quality care and optimise the patient experience," Austco CEO Clayton Astles said.

"Our exceptional Tacera nurse call system is integral to quality operation of any hospital and our technology drives productivity and ensures improvement in patient care," he added.

On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.


Subscribe


AZV by the numbers
More From The Market Herald
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) updates market on December quarter

Imagion Biosystems (IBX) has updated the market regarding its activities and cash flow during the December quarter.
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) proceeds to higher dose of PD1-VAXX in clinical trial

Imugene (IMU) has announced the Cohort Review Committee (CRC) has confirmed its phase one clinical trial for PD1-Vaxx will proceed to the second
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) wins $1.4M grant for COVID-19 test development

Chemistry company AnteoTech (ADO) has been awarded a $1.4 million grant from the Queensland State Government.
Fiji Kava (ASX:FIJ) appoints Jack Lowenstein as Non-Executive Director

" Fiji Kava (ASX:FIJ) increases revenue by 94pc in December quarter

Fiji Kava (FIJ) has recorded some strong results in its latest quarterly report, including a 94 per cent increase in revenue.